Market Cap
$952.8M
KURA
Kura Oncology, Inc.
$10.65 ▲ +0.00%
Prev close $10.65Market cap$952.8M
ConsensusStrong Buy
12-mo target$31.85 (+199.0%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (6 insiders)High Impact Filing (7/10)31 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on KURA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$554.4M
Inst. Activity
31 buys / 16 sells
Insider Activity
$2.4M buy / $2.7M sell
Insider Net $
-$343.0K
SEC Reports
14
Press Releases
7
Price chart 30d -19.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a b
Sep 29, 2026 Insider
FORD KATHLEEN sold 3,668 shares
Chief Operating Officer @ $10.75 ($39.4K)
Sep 29, 2026 Insider
Leoni Mollie sold 28,802 shares
Chief Medical Officer @ $10.75 ($309.6K)
Sep 29, 2026 Insider
Sep 9, 2026 SEC Powl Brian T. sold 15,430 shares
Chief Commercial Officer @ $10.75 ($165.9K)
Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E. Wilson and Thomas Doyle in those roles, effective Septem
8-K — Impact 2/10
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for di
8-K — Impact 6/10
Kura Oncology CEO Troy Wilson purchased $1.24M in open-market shares at ~$12.39, while the Chief Legal Officer and Chief
CLUSTER — Impact 6/10
Kura Oncology announced an oral presentation of updated Phase 1a data from its FIT-001 trial of darlifarnib plus cabozan
Impact 5/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 22 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | JP Morgan | INITIATE | Overweight | 55% |
| Aug 24, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Aug 13, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Jul 28, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Jun 15, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Apr 14, 2026 | Lake Street | INITIATE | Buy | 45% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 13 | 3 | 0 | 0 | 86% | |
| Aug 1, 2026 | 6 | 13 | 3 | 0 | 0 | 86% | |
| Jul 1, 2026 | 6 | 13 | 3 | 0 | 0 | 86% | |
| Jun 1, 2026 | 6 | 13 | 3 | 0 | 0 | 86% | |
| May 1, 2026 | 6 | 13 | 3 | 0 | 0 | 86% | |
| Apr 1, 2026 | 6 | 12 | 3 | 0 | 0 | 86% | |
| Mar 1, 2026 | 6 | 12 | 3 | 0 | 0 | 86% | |
| Feb 1, 2026 | 6 | 12 | 3 | 0 | 0 | 86% |
Price targets
Where 13 covering analysts think KURA trades over the next 12 months.
$31.85 +199.0% upside Strong Buy
Current$10.65 Low$15.00 Median$28.00 High$76.00 13 analysts
$15.00$76.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 6 bullish, 0 bearish, 1 mixed, 7 neutral · avg impact 4.5/10.Plus 7 press releases.
NEUTRAL8-K2/10
Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E. Wilson and Thomas Doyle in those rol
Sep 9, 2026
BULLISH8-K6/10
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation men
Sep 9, 2026
BULLISHCLUSTER6/10
Kura Oncology CEO Troy Wilson purchased $1.24M in open-market shares at ~$12.39, while the Chief Leg
Aug 25, 2026
BULLISHCLUSTER6/10
Kura Oncology CEO Troy Wilson purchased $1.11M of stock on the open market at $11.12/share, while Ch
Aug 22, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medi
Oct 1, 2026
short_volume
Short Volume: KURA — 64.0% short (0.6M / 1.0M)
Short: 649,988 | Exempt: 0 | TRF Vol: 1,015,066 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: KURA — 57.4% short (0.3M / 0.5M)
Short: 307,601 | Exempt: 2,176 | TRF Vol: 536,036 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
fda
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
– KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
Sep 29, 2026
short_volume
Short Volume: KURA — 61.7% short (0.4M / 0.7M)
Short: 429,834 | Exempt: 0 | TRF Vol: 696,555 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.81 | $-0.99–$-0.70 | 5.2% | +0.1% | 7↑ 0↓ | $0.0B | 10 |
| Next Q | $-0.79 | $-0.95–$-0.68 | 14.3% | -0.8% | 5↑ 1↓ | $0.0B | 10 |
| Current FY | $-3.17 | $-3.48–$-2.98 | 0.2% | -0.3% | 7↑ 0↓ | $0.1B | 10 |
| Next FY | $-2.35 | $-3.26–$-1.58 | 26.0% | -2.3% | 7↑ 0↓ | $0.2B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.806 | — |
| 7d ago | $-0.807 | +0.001 |
| 30d ago | $-0.807 | +0.001 |
| 60d ago | $-0.892 | +0.086 |
| 90d ago | $-0.901 | +0.095 |
Institutional ownership
Which big funds own KURA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $554.4M total value (50,549,479 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 31 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | $115.3M | 20.8% | — |
| STATE STREET CORP | 5,329,208 | $58.5M | 10.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,916,164 | $43.0M | 7.7% | — |
| AQR CAPITAL MANAGEMENT LLC | 3,126,727 | $34.3M | 6.2% | TRIM -30.6% |
| GOLDMAN SACHS GROUP INC | 2,265,171 | $24.8M | 4.5% | ADD +58.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,229,958 | $24.5M | 4.4% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,663,765 | $18.3M | 3.3% | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,410,275 | $15.5M | 2.8% | NEW |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,329,941 | $14.6M | 2.6% | — |
| Qube Research & Technologies Ltd | 1,169,884 | $12.8M | 2.3% | TRIM -28.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | 1,433,471 | 2,265,171 | +58.0% | $24.8M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | — | 1,410,275 | — | $15.5M |
| Qube Research & Technologies Ltd | TRIM | 1,636,733 | 1,169,884 | -28.5% | $12.8M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | ADD | 602,231 | 948,974 | +57.6% | $10.4M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 1,565,143 | 711,332 | -54.6% | $7.8M |
| Jump Financial, LLC | ADD | 505,452 | 675,044 | +33.6% | $7.4M |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 41,280 | 267,950 | +549.1% | $2.9M |
| JPMORGAN CHASE & CO | DOUBLED | 52,572 | 245,920 | +367.8% | $2.7M |
| Quantinno Capital Management LP | DOUBLED | 89,303 | 206,728 | +131.5% | $2.3M |
| Trexquant Investment LP | TRIM | 528,704 | 183,731 | -65.2% | $2.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 29 transactions. Net -$343.0K — $2.4M bought, $2.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | FORD KATHLEEN | Chief Operating Officer | SELL | 3,668 | $10.75 | $39.4K |
| Sep 29, 2026 | Leoni Mollie | Chief Medical Officer | SELL | 28,802 | $10.75 | $309.6K |
| Sep 29, 2026 | Powl Brian T. | Chief Commercial Officer | SELL | 15,430 | $10.75 | $165.9K |
| Sep 28, 2026 | FORD KATHLEEN | Chief Operating Officer | SELL | 6,906 | $10.50 | $72.5K |
| Sep 28, 2026 | Leoni Mollie | Chief Medical Officer | SELL | 12,448 | $10.50 | $130.7K |
| Sep 28, 2026 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | SELL | 4,607 | $10.50 | $48.4K |
| Sep 28, 2026 | Powl Brian T. | Chief Commercial Officer | SELL | 9,020 | $10.50 | $94.7K |
| Sep 28, 2026 | Powl Brian T. | Chief Commercial Officer | SELL | 8,000 | $10.56 | $84.5K |
| Sep 28, 2026 | Bair Teresa Brophy | Chief Legal Officer | SELL | 8,442 | $10.50 | $88.6K |
| Sep 24, 2026 | Burrows Francis | Chief Scientific Officer | SELL | 20,726 | $10.83 | $224.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KURA.
Shares short
14,820,592
Settlement Sep 15, 2026
Change vs prior
+10.5%
Semi-monthly cycle
Days to cover
8.8
At avg daily volume
Of shares outstanding
≈16.7%
Estimate — not % of float
All KURA filing & press-release reports (21)
- 8-K reportSep 9, 2026
- 8-K reportSep 9, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 22, 2026
- INSIDER-BUY reportAug 17, 2026
- PRESS-RELEASE reportAug 12, 2026
- PRESS-RELEASE reportAug 5, 2026
- 8-K reportJul 29, 2026
- PRESS-RELEASE reportJul 14, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportJun 2, 2026
- DEFA14A reportMay 26, 2026
- PRESS-RELEASE reportMay 26, 2026
- CLUSTER reportMay 22, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportApr 17, 2026
- DEFA14A reportApr 10, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026